Last reviewed · How we verify
Degludec insulin
Degludec insulin is a Small molecule drug developed by King Faisal Specialist Hospital & Research Center. It is currently FDA-approved.
Degludec insulin, marketed by King Faisal Specialist Hospital & Research Center, is a long-acting insulin analog with a key composition patent expiring in 2028. Its primary strength lies in its extended duration of action, which provides stable glucose control. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Degludec insulin |
|---|---|
| Sponsor | King Faisal Specialist Hospital & Research Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes (PHASE1)
- The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants. (NA)
- A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin (PHASE2)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (PHASE2)
- Single-ascending Dose Study of HEC-151 Injection (PHASE1)
- A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) (PHASE1)
- A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Degludec insulin CI brief — competitive landscape report
- Degludec insulin updates RSS · CI watch RSS
- King Faisal Specialist Hospital & Research Center portfolio CI
Frequently asked questions about Degludec insulin
What is Degludec insulin?
Who makes Degludec insulin?
What development phase is Degludec insulin in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing